David M. Gershenson, MD, discusses the results of the phase 3 MILO trial in low-grade serous ovarian cancer.
David M. Gershenson, MD
Advertisement
Articles by David M. Gershenson, MD
David M. Gershenson, MD, professor, Obstetrics, Gynecology and Reproductive Sciences, The University of Texas MD Anderson Cancer Center, discusses the evolution of targeted therapies for patients with rare gynecologic malignancies.
Advertisement
Latest Updated Articles
Dr. Gershenson on Evolution of Targeted Therapies for Rare Gynecologic MalignanciesPublished: February 11th 2016 | Updated:
Advertisement
Advertisement
Trending on OncLive
1
Ultra-Sensitive ctDNA and CSF Liquid Biopsy May Refine Monitoring and Adaptive Trial Designs in Metastatic Breast Cancer
2
Lurbinectedin-Based Triplet Shows Clinical Benefit in Advanced Soft Tissue Sarcoma
3
FDA Grants Fast Track Designation to IBI3003 in Relapsed/Refractory Multiple Myeloma
4
Anti–Gremlin-1 Therapy Plus Chemo Makes Waves in GI Malignancies
5